A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Inclusion Criteria:
Exclusion Criteria:
information.center@astrazeneca.com1-877-240-9479
CABA, C1120AAC, Argentina
Caba, C1128AAF, Argentina
Ciudad de Buenos Aires, C1094AAD, Argentina
Jinzhou Shi, 121001, China
Liangyugang, 222002, China
Pohlheim, 35415, Germany
Hachioji-shi, 192-0083, Japan
Ichikawa-shi, 272-8516, Japan
Kishiwada-shi, 596-8501, Japan
Meguro-ku, 153-0053, Japan
Shinjuku-ku, 160-0008, Japan
Tama-shi, 206-0033, Japan
Yamato-shi, 242-0004, Japan
Sarawak Miri, 98000, Malaysia
Tainan County, 71044, Taiwan
Banphaeo, 74120, Thailand
Muang, 70000, Thailand
Mueang, 20000, Thailand
Hochiminh City, 700000, Vietnam
Hochiminh, 700000, Vietnam
Hồ Chí Minh, 700000, Vietnam